Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Genitourinary (Prostate) Cancer

Type: Poster Session

Time: Monday June 5, 1:15 PM to 4:45 PM

Location: Hall A

Translating prostate cancer working group (PCWG) criteria into a quantitative progression biomarker in metastatic castration resistant prostate cancer (mCRPC).

Sub-category:
Biomarkers/Epidemiology/Outcomes

Category:
Genitourinary (Prostate) Cancer

Meeting:
2017 ASCO Annual Meeting

Abstract No:
5068

Poster Board Number:
Poster Session (Board #142)

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 5068)

Author(s): Aseem Anand, Glenn Heller, Howard I. Scher, Michael J. Morris; Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY; Memorial Sloan-Kettering Cancer Center and Weil Cornell Medical College, New York, NY

Abstract Disclosures

Abstract:

Background: mCRPC is a bone dominant lethal disease. A validated endpoint in mCRPC trials is bone scan progression, which is semi-quantitative and rely on the appearance of new lesions as proposed by the PCWG. The validated automated bone scan index (BSI) quantifies the bone tumor burden as the fraction of total skeletal weight. To build on the current definition of disease progression, we sought to compare the association of time to progression with overall survival (OS) using PCWG criteria and BSI increase. Methods: mCRPC patients (pts) enrolled on trials of agents targeting androgen-receptor (AR) were assessed. Pts were required to have a raw bone scan image for BSI analysis concurrent with disease assessments. The EXINI automated computing platform generated the BSI values. Thresholds for the absolute and relative increase in BSI from 1st follow-up (≤12 weeks) were explored for the time to BSI progression. The association with survival time was computed for each threshold defined time to BSI progression. Kendall’s Tau, derived from the Clayton copula, was used to associate time to BSI progression with survival time, where both endpoints may be censored. Results: A total of 257 pts were assessed, of whom 169 had raw bone scans images needed for the BSI analysis. 90 pts (53%) met progression by PCWG criteria, the association between the time to PCWG progression and OS was 0.52. The association between time to BSI progression and OS was comparable to the PCWG progression when the absolute increase in BSI was 0.6 or more (table below). Conclusions: Progression in bone can be expressed as a single quantitative metric that describes the increase in total disease burden while retaining the same association that PCWG has with OS. These data represent the first steps to a quantitative expression of bone disease progression as a clinical trials endpoint.

Proportion progressedOS correlation
Absolute BSI increase
0.20.580.34
0.40.470.41
0.60.410.51
0.80.360.52
1.00.290.52
Relative BSI Increase
30%0.530.25
60%0.390.29
90%0.310.41
120%0.260.49
150%0.230.50

 
Other Abstracts in this Sub-Category:

 

1. Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk.

Meeting: 2017 ASCO Annual Meeting Abstract No: 5000 First Author: Daniel Eidelberg Spratt
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes

 

2. Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC).

Meeting: 2017 ASCO Annual Meeting Abstract No: 5006 First Author: Andrew J. Armstrong
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes

 

3. Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials.

Meeting: 2017 ASCO Annual Meeting Abstract No: 5007 First Author: Glenn Heller
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes

 

More...